The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer DOI Open Access

Meilan Zhang,

Zhaokuan Zheng,

Shouliang Wang

et al.

Cancer Drug Resistance, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 19, 2024

MicroRNAs (miRNAs) are small non-coding RNAs comprising 19-24 nucleotides that indirectly control gene expression. In contrast to other (ncRNAs), circular (circRNAs) defined by their covalently closed loops, forming covalent bonds between the 3’ and 5’ ends. circRNAs regulate expression interacting with miRNAs at transcriptional or post-transcriptional levels. Accordingly, many biological events related cancer, including cell proliferation, metabolism, cycle, apoptosis. Both involved in pathogenesis of diseases, such as breast cancer. This review focuses on latest discoveries dysregulated highlighting potential biomarkers for clinical diagnosis, prognosis, chemotherapy response.

Language: Английский

Autophagy-driven regulation of cisplatin response in human cancers: Exploring molecular and cell death dynamics DOI Creative Commons
Yang Yang,

Lixia Liu,

Yu Tian

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 587, P. 216659 - 216659

Published: Feb. 15, 2024

Despite the challenges posed by drug resistance and side effects, chemotherapy remains a pivotal strategy in cancer treatment. A key issue this context is macroautophagy (commonly known as autophagy), dysregulated cell death mechanism often observed during chemotherapy. Autophagy plays cytoprotective role maintaining cellular homeostasis recycling organelles, emerging evidence points to its significant promoting progression. Cisplatin, DNA-intercalating agent for inducing cycle arrest, encounters treatments. Recent studies have shown that autophagy can contribute cisplatin or insensitivity tumor cells through various mechanisms. This be mediated protective autophagy, which suppresses apoptosis. Additionally, autophagy-related changes metastasis, particularly induction of Epithelial-Mesenchymal Transition (EMT), also lead resistance. Nevertheless, pharmacological strategies targeting regulation apoptosis offer promising avenues enhance sensitivity therapy. Notably, numerous non-coding RNAs been identified regulators Thus, therapeutic associated pathways holds potential restoring sensitivity, highlighting an important direction future clinical research.

Language: Английский

Citations

73
Circular RNAs in breast cancer diagnosis, treatment and prognosis DOI Creative Commons

X. Huang,

Cailu Song,

JINHUI ZHANG

et al.

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Journal Year: 2023, Volume and Issue: 32(2), P. 241 - 249

Published: Dec. 7, 2023

Breast cancer has surpassed lung to become the most common malignancy worldwide. The incidence rate and mortality of breast continue rise, which leads a great burden on public health. Circular RNAs (circRNAs), new class noncoding (ncRNAs), have been recognized as important oncogenes or suppressors in regulating initiation progression. In cancer, circRNAs significant roles tumorigenesis, recurrence multidrug resistance that are mediated by various mechanisms. Therefore, may serve promising targets therapeutic strategies for management. This study reviews recent studies about biosynthesis characteristics diagnosis, treatment prognosis evaluation, well value clinical applications biomarkers cancer. Understanding mechanisms function could help transform basic research into facilitate development novel circRNA-based treatment.

Language: Английский

Citations

57
CircPVT1 promotes ER‐positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS DOI Creative Commons
Yi Jia, Lei Wang,

Guo‐sheng Hu

et al.

The EMBO Journal, Journal Year: 2023, Volume and Issue: 42(10)

Published: April 3, 2023

Abstract The molecular mechanisms underlying estrogen receptor (ER)‐positive breast carcinogenesis and endocrine therapy resistance remain incompletely understood. Here, we report that circPVT1, a circular RNA generated from the lncRNA PVT1, is highly expressed in ERα‐positive cancer cell lines tumor samples functionally important promoting tumorigenesis resistance. CircPVT1 acts as competing endogenous (ceRNA) to sponge miR‐181a‐2‐3p, expression of ESR1 downstream ERα‐target genes growth. Furthermore, circPVT1 directly interacts with MAVS protein disrupt RIGI–MAVS complex formation, inhibiting type I interferon (IFN) signaling pathway anti‐tumor immunity. Anti‐sense oligonucleotide (ASO)‐targeting inhibits growth, re‐sensitizing tamoxifen‐resistant cells tamoxifen treatment. Taken together, our data demonstrated can work through both ceRNA scaffolding promote cancer. Thus, may serve diagnostic biomarker therapeutic target for clinic.

Language: Английский

Citations

46
Mechanisms and therapeutic implications of gene expression regulation by circRNA-protein interactions in cancer DOI Creative Commons
Nan Zhang, Xinjia Wang, Yu Li

et al.

Communications Biology, Journal Year: 2025, Volume and Issue: 8(1)

Published: Jan. 17, 2025

Circular RNAs (circRNAs) have garnered substantial attention due to their distinctive circular structure and gene regulatory functions, establishing them as a significant class of functional non-coding in eukaryotes. Studies demonstrated that circRNAs can interact with RNA-binding proteins (RBPs), which play crucial roles tumorigenesis, metastasis, drug response cancer by influencing expression altering the processes tumor initiation progression. This review aims summarize recent advances research on circRNA-protein interactions (CPIs) discuss functions mode action CPIs at various stages expression, including transcription, splicing, translation, post-translational modifications context cancer. Additionally, we explore role resistance gain deeper understanding potential applications development new anti-cancer therapeutic approaches.

Language: Английский

Citations

2
Role of circular RNAs in cancer therapy resistance DOI Creative Commons
Wenjuan Liu,

Jiling Niu,

Yanfei Huo

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: Feb. 25, 2025

Over the past decade, circular RNAs (circRNAs) have gained recognition as a novel class of genetic molecules, many which are implicated in cancer pathogenesis via different mechanisms, including drug resistance, immune escape, and radio-resistance. ExosomalcircRNAs, particular, facilitatecommunication between tumour cells micro-environmental cells, fibroblasts, other components. Notably, can reportedly influence progression treatment resistance by releasing exosomalcircRNAs. circRNAs often exhibit tissue- cancer-specific expression patterns, growing evidence highlights their potential clinical relevance utility. These molecules show strong promise biomarkers therapeutic targets for diagnosis treatment. Therefore, this review aimed to briefly discuss latest findings on roles mechanisms key various malignancies, lung, breast, liver, colorectal, gastric cancers, well haematological malignancies neuroblastoma.This will contribute identification new circRNA early cancer.

Language: Английский

Citations

2
Recent advances and perspectives on the development of circular RNA cancer vaccines DOI Creative Commons
Zhaohui Gong, Wentao Hu, Chengwei Zhou

et al.

npj Vaccines, Journal Year: 2025, Volume and Issue: 10(1)

Published: March 1, 2025

Engineered circular RNAs (circRNAs) are emerging as promising platforms for RNA-based vaccines in cancer treatment. We summarize the recent advances of design, synthesis, and delivery circRNA-based vaccines, highlight applications challenges circRNA therapy. Further enhancements required areas such antigen selection, targeted delivery, multidimensional crosstalks, clinical trial assessments to advance efficacy safety cancer.

Language: Английский

Citations

2
CircRNF10 triggers a positive feedback loop to facilitate progression of glioblastoma via redeploying the ferroptosis defense in GSCs DOI Creative Commons
Chengbin Wang, Minjie Zhang, Yingliang Liu

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2023, Volume and Issue: 42(1)

Published: Sept. 19, 2023

Glioma exhibit heterogeneous susceptibility for targeted ferroptosis. How circRNAs alterations in glioma promote iron metabolism and ferroptosis defense remains unclarified.The highly enriched glioblastoma (GBM) were obtained through analysis of sequencing datasets. Quantitative real-time PCR (qRT-PCR) was used to determine the expression circRNF10 normal brain tissue. Both gain-of-function loss-of-function studies assess effects on using vitro vivo assays. The hypothesis that ZBTB48 promotes established bioinformatics functional RNA pull-down immunoprecipitation (RIP) assays performed examine interaction between target proteins including ZBTB48, MKRN3 IGF2BP3. posttranslational modification mechanism verified coimmunoprecipitation (co-IP) ubiquitination transcription activation HSPB1 IGF2BP3 by confirmed luciferase reporter gene chromatin (ChIP) stabilizing effect explored actinomycin D assay. Finally, a series experiments explore influences progression.A novel circular RNA, hsa_circ_0028912 (named circRNF10), which is significantly upregulated tissues correlated with patients' poor prognosis. Through integrated circRNA-proteins datasets results, we reveal as transcriptional factor binding circRNF10, notably promoting upregulation remodel facilitates launch circRNF10/ZBTB48/IGF2BP3 positive feedback loop GSCs. Additionally, can competitively bind block E3 ubiquitin ligase activity enhance expression. Consequently, circRNF10-overexpressed stem cells (GSCs) display lower Fe2+ accumulation, selectively priming tumors evading.Our research presents abnormal causing molecular metabolic change glioma, leverage discover therapeutically exploitable vulnerability

Language: Английский

Citations

25
Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis of cancer stem cells from hepatocellular carcinoma DOI Open Access
Ruijiao Kong,

Wenxin Wei,

Qiuhong Man

et al.

Cancer Letters, Journal Year: 2023, Volume and Issue: 578, P. 216442 - 216442

Published: Oct. 16, 2023

Language: Английский

Citations

23
Non-coding RNAs: emerging biomarkers and therapeutic targets in cancer and inflammatory diseases DOI Creative Commons
Basma Hossam Abdelmonem,

Lereen T. Kamal,

Lilian Waheed Wardy

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: March 10, 2025

Non-coding RNAs (ncRNAs) have a significant role in gene regulation, especially cancer and inflammatory diseases. ncRNAs, such as microRNA, long non-coding RNAs, circular alter the transcriptional, post-transcriptional, epigenetic expression levels. These molecules act biomarkers possible therapeutic targets because aberrant ncRNA has been directly connected to tumor progression, metastasis, response therapy research. ncRNAs’ interactions with multiple cellular pathways, including MAPK, Wnt, PI3K/AKT/mTOR, impact processes like proliferation, apoptosis, immune responses. The potential of RNA-based therapeutics, anti-microRNA microRNA mimics, restore normal is being actively studied. Additionally, tissue-specific patterns ncRNAs offer unique opportunities for targeted therapy. Specificity, stability, responses are obstacles use ncRNAs; however, novel strategies, modified oligonucleotides delivery systems, developed. profiling may result more individualized successful treatments precision medicine advances, improving patient outcomes creating early diagnosis monitoring opportunities. current review aims investigate roles diseases, focusing on their mechanisms regulation implications non-invasive diagnostics therapies. A comprehensive literature was conducted using PubMed Google Scholar, research published between 2014 2025. Studies were selected based rigorous inclusion criteria, peer-reviewed status relevance Non-English, non-peer-reviewed, inconclusive studies excluded. This approach ensures that findings presented high-quality relevant sources.

Language: Английский

Citations

1
Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217/G3BP2 signaling pathway DOI Creative Commons
Wenjie Xia, Wuzhen Chen, Chao Ni

et al.

Breast Cancer Research, Journal Year: 2023, Volume and Issue: 25(1)

Published: July 17, 2023

Chemoresistance involves metastasis and aggressiveness of breast cancer (BC). Chemotherapy-elicited exosomes have been reported to be associated with drug resistance pro-metastatic capacity BC cells. Non-coding RNAs (ncRNAs) are enriched in exosomes, which participated generation, progression, BC. However, the mechanism underlying chemoresistance cells mediated by BC-derived exosomal ncRNAs remained elucidated.The effects PTX-induced circBACH1 on cell function were assessed using RNA Binding Protein Immunoprecipitation (RIP), dual luciferase reporter gene, tube formation, CCK-8, Western Blot assays. The miR-217 expression levels detected quantitative real-time PCR (RT-qPCR) Immunohistochemistry (IHC) assays tissues precancerous patients.CircBACH1 was increased paclitaxel-treated (PTX-EXO) tissue. PTX-EXO shown promote PTX-resistance angiogenesis through upregulation circBACH1. Downregulation improved PTX-sensitiveness suppressing viability, stemness, migration, Moreover, we found that interacted targeted GTPase-activating SH3 domain-binding protein 2 (G3BP2) CircBACH1 combined cotransfection suppressed G3BP2 proteins compared treatment MCF-7 In addition, downregulation migration.These results demonstrated promoted stemness migration sponging upregulate G3BP2, provided a new therapeutic target for progression via circBACH1/miR-217/G3BP2 axis.

Language: Английский

Citations

20